复方卤倍他索丙酸酯（0.01%）和曲妥拉汀（0.045%）洗剂（HP/TAZ）已获批用于成人斑块型银屑病的治疗，经过3期临床试验已证明其疗效和安全性。本研究探讨了HP/TAZ对肿瘤坏死因子α（TNF-α）和白细胞介素17A（IL-17A）的减少及其与银屑病改善之间的相关性。10名轻中度斑块型银屑病患者的两块对称的斑块自行涂抹HP/TAZ（治疗斑块）或安慰剂洗剂（未治疗斑块）进行12周。在基线和每次研究访视（第2、4、8和12周），评估了研究者全球评定（IGA）评分、红斑、脱屑和硬化。此外，采用D-squame胶带条通过酶联免疫吸附试验定量测定靶损伤中的TNF-α和IL-17A水平。HP/TAZ治疗组与未治疗斑块相比，在第2周至第12周的IGA评分均显著改善（p < 0.003）。HP/TAZ显著降低了治疗斑块中第4周至第12周的TNF-α水平（p < 0.03）和第2周至第8周的IL-17A水平（p < 0.05）。HP/TAZ在治疗银屑病斑块方面表现出较高的有效性，并且尽管HP/TAZ不是生物制剂，但有效减少了驱动银屑病的细胞因子相关炎症标志物。

Fixed-combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) is approved for the treatment of plaque psoriasis in adults, with a demonstrated efficacy and safety profile in phase 3 trials. This study examined the effect of HP/TAZ on the reduction of tumor necrosis factor alpha (TNF-α) and interleukin 17 A (IL-17A) and its correlation to psoriasis improvement.Ten adults with mild-to-moderate plaque psoriasis and 2 symmetrical plaques self-applied HP/TAZ (treated plaque) or vehicle lotion (untreated plaque) for 12 weeks. At baseline and each study visit (weeks 2, 4, 8, and 12), Investigator's Global Assessment (IGA) score and erythema, scaling, and induration were assessed. Additionally, D-squame tape strips were utilized to quantify TNF-α and IL-17A in target lesions by enzyme-linked immunosorbent assay.Significant improvements in mean IGA score in HP/TAZ-treated compared with untreated plaques were evident at week 2 and maintained through week 12 (p < 0.003). HP/TAZ significantly reduced TNF-α levels at weeks 4 through 12 (p < 0.03) and IL-17A levels at weeks 2 through 8 (p < 0.05) in treated compared with untreated plaques.HP/TAZ was highly effective in treating psoriasis plaques and, although HP/TAZ is not a biologic, effectively reduced cytokine-associated inflammatory markers that drive psoriatic disease.